ANI Pharmaceuticals Reports Q3 Results, Raises Adjusted EBITDA and EPS Guidance
Quarterly net revenue rose 27.6% year over year. ANI narrowed 2026 revenue guidance to $1,085–$1,125 million and raised adjusted non-GAAP EBITDA guidance to $290–$300 million. Adjusted diluted EPS was $2.70 for the quarter, with full-year guidance raised to $9.37–$9.71.
The company achieved a 27.6% year-over-year increase in quarterly net revenue, driven by solid growth in its Purified Cortrophin Gel and Generics businesses. ANI narrowed its 2026 total revenue guidance to $1,085—$1,125 million and raised its adjusted non-GAAP EBITDA guidance to $290—$300 million. Additionally, the company reported adjusted non-GAAP diluted earnings per share of $2.70 for the quarter and raised its full-year outlook for this metric to $9.37—$9.71. Management attributed the performance to momentum in the gout expansion and continued operational success.